Scarica l'app Stockscreener
78.39
0.99%
-0.78
Pre-mercato:
78.51
0.12
+0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$79.17
Aprire:
$79.55
Volume 24 ore:
16.04M
Relative Volume:
1.01
Capitalizzazione di mercato:
$195.89B
Reddito:
$64.17B
Utile/perdita netta:
$17.12B
Rapporto P/E:
11.65
EPS:
6.73
Flusso di cassa netto:
$18.10B
1 W Prestazione:
-0.71%
1M Prestazione:
-17.11%
6M Prestazione:
-29.71%
1 anno Prestazione:
-37.88%
Intervallo 1D:
$77.72
$79.96
Intervallo di 1 settimana:
$75.96
$81.99
Portata 52W:
$75.96
$134.63
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
Confronta MRK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
78.39 | 195.89B | 64.17B | 17.12B | 18.10B | 6.73 |
|
LLY
Lilly Eli Co
|
757.18 | 680.08B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
153.62 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
ABBV
Abbvie Inc
|
176.80 | 312.76B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
64.49 | 286.27B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.93 | 217.12B | 51.72B | 11.94B | 13.81B | 5.88 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Downgrade | TD Cowen | Buy → Hold |
| 2025-01-08 | Downgrade | Truist | Buy → Hold |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Hold |
| 2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
| 2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Iniziato | Jefferies | Buy |
| 2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
| 2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-16 | Iniziato | Daiwa Securities | Neutral |
| 2021-12-13 | Downgrade | UBS | Buy → Neutral |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-01 | Aggiornamento | Argus | Hold → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-20 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-16 | Iniziato | SVB Leerink | Outperform |
| 2019-07-03 | Iniziato | Mizuho | Buy |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Reiterato | Citigroup | Buy |
| 2018-10-09 | Ripresa | Guggenheim | Buy |
| 2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
Rep. Kelly Morrison Sells Off Shares of Merck & Co., Inc. (NYSE:MRK) - Defense World
Price Over Earnings Overview: Merck & Co - Benzinga
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery - Benzinga
April 14, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRK - TradingView
Merck & Co. Inc. (MRK): Among the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance
Rep. Marjorie Taylor Greene Buys Merck & Co., Inc. (NYSE:MRK) Stock - Defense World
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming DeadlinesMRK - PR Newswire
Merck to Integrate Medical Resources Into Microsoft's Health Care AI Platform - MarketScreener
Is Merck & Co. (NYSE:MRK) a Cheap NYSE Stock to Invest in According to Hedge Funds? - Insider Monkey
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - Business Wire
What to Expect From Merck & Co.'s Next Quarterly Earnings Report - TradingView
What To Expect From Merck & Co.'s Next Quarterly Earnings Report - Barchart.com
Levi & Korsinsky Notifies Shareholders of Merck & Co., Inc. (MRK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MRK Investors Have Final Opportunity Today to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Is Merck & Co., Inc. (MRK) the Best Medical Stock to Buy According to Billionaires? - Insider Monkey
MRK Deadline Tomorrow: MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - PR Newswire
FINAL MRK DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Merck & Co., Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
MRK DEADLINE MONDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Merck & Co., Inc. - Bluefield Daily Telegraph
MRK DEADLINE MONDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – MRK - GlobeNewswire Inc.
Merck & Co., Inc. Investors: Please contact the Portnoy Law - GlobeNewswire
Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion - TradingView
Jim Cramer on Merck (MRK): Stay The Course… It’s Been a Real Tough One - Yahoo Finance
MRK STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
MRK Lawsuit Alert! Class Action Lawsuit Against Merck & Company - TipRanks
Investors who lost money on Merck & Co., Inc.(MRK) should contact Levi & Korsinsky about pending Class ActionMRK - PR Newswire
Merck (MRK) Faces Shareholder Proposals Amid Market Challenges - GuruFocus
Merck (MRK) Poised for Growth with Strong Financial Performance - GuruFocus
Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion - TradingView
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors – Contact - Bluefield Daily Telegraph
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - PR Newswire
Merck & Co., Inc. (MRK): A Bull Case Theory - Insider Monkey
Investor Sues Merck Executives, Board Over Misleading Comments - Bloomberg Law News
Merck & Co Inc Says CEO Robert M. Davis's 2024 Total Compensation Was $23.2 MillionSEC Filing - MarketScreener
MRK FINAL DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action – MRK - TradingView
Investors who lost money on Merck & Co., Inc. (MRK) should contact The Gross Law Firm about - Bluefield Daily Telegraph
Deadline Alert: Merck & Co (MRK) Investors Who Lost Money - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Merck & Co., Inc. to Contact the Firm Today! - markets.businessinsider.com
Key Trends Shaping the Future of Pulmonary Arterial Hypertension Market:Merck & Co. Introduces Innovative F... - WhaTech
Merck & Co., Inc. (MRK): Among Defensive Stocks Billionaire Ken Fisher is Betting On - Yahoo Finance
2025-04-08 | MRK LAWSUIT ALERT: Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NYSE:MRK | Press Release - Stockhouse
MRK Stock Price and Chart — NYSE:MRK - TradingView
Infertility Drugs Market Is Booming Worldwide 2025-2032 | Merck & Co., Inc., Ferring Pharmaceuticals - openPR.com
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Merck & Co., Inc. to Contact the Firm Today! - markets.businessinsider.com
Goldman Sachs raises Merck stock rating to Buy, target to $103 - Investing.com
Lost Money on Merck & Co., Inc. (MRK)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
MRK Deadline: MRK Purchasers with Losses in Excess of $100K Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - Morningstar
MRK FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action – MRK - TradingView
Merck & Co., Inc. Sued for Securities Law Violations - GlobeNewswire
Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal - insights.citeline.com
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.43%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):